Endocyte Announces Updated Data on EC1456 and EC1169 at the

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Endocyte Announces Updated Data on EC1456 and EC1169 at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting

WEST LAFAYETTE, Ind., May 13, 2015 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq: ECYT ) a biopharmaceutical company and leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy in cancer and other serious diseases, today announced that data featuring Endocyte's SMDC, EC1456 will be presented at the 51 st Annual Meeting of the American Society of Clinical Oncology (ASCO) being held May 29 - June 2, 2015, in Chicago.

The EC1456 poster shows that EC1456 is generally well tolerated in previously treated cancer patients, with no treatment-related deaths, SAE's, dose modifications, or Grade 4 toxicities on either schedule. There is also no evidence of cumulative or late emerging toxicity, thus far. Grade 1-2 toxicities include nausea, vomiting, stomatitis, abdominal pain, constipation, diarrhea, paresthesia, and fatigue. Cohort expansions are continuing at 4.5 mg/m 2 (weekly schedule) and 2.5 mg/m 2 (biweekly schedule). Anti-tumor activity with EC1456 is suggested by prolonged stable disease in FR+ patients: 11/20 patients had stable disease as their best study response. EC1456 shows a dose-dependent PK profile that has prolonged drug concentration above IC 50 and is more favorable than the 1 st generation SMDC, vintafolide.

The poster will be available on Endocyte's website following presentation at the conference.

Presentation is as follows:
   
Abstract #: 2551
Title: Phase 1 study of the folic acid (FA) and tubulysin B hydrazide (TubBH) small molecule drug conjugate (SMDC) EC1456 in patients (pts) with advanced cancer (CA)
Presenter: Daniela Matei, M.D., Indiana University Simon Cancer Center
When: Saturday, May 30, 8 a.m. – 11:30 a.m. EDT
Session Title: Developmental Therapeutics – Clinical Pharmacology and Experimental Therapeutics
Location: S Hall A

The abstract for EC1169, titled "Phase 1 study of the PSMA-tubulysin small molecule drug conjugate EC1169 in pts with metastatic castrate-resistant prostate cancer (mCRPC)" will be published in the ASCO 2015 Abstract Book. The abstract will provide an update on the safety and efficacy observed in the ongoing phase 1 dose escalation trial.

About EC1456

EC1456 is an investigational proprietary, injectable, SMDC consisting of folate (vitamin B9) linked to a potent cytotoxic agent, tubulysin B hydrazide (TubBH). EC1456 is wholly owned by Endocyte. TubBH is a member of the tubulysin class of anti-neoplastic agents that inhibit the polymerization of tubulin into microtubules, a critical component during cell division. The targeting ligand folate, essential for cell division, has been investigated with vintafolide. EC1456 is currently being evaluated in a Phase 1 study in patients with advanced solid tumors (ClinicalTrials.gov Identifier: NCT01999738 ).

About EC1169

EC1169 is an investigational proprietary, injectable, SMDC consisting of a PSMA targeting ligand (DUPA analog) linked to a potent cytotoxic agent, tubulysin B hydrazide (TubBH). EC1169 is wholly owned by Endocyte. TubBH is a member of the tubulysin class of anti-neoplastic agents that inhibit the polymerization of tubulin into microtubules, a critical component during cell division. EC1169 is currently being evaluated in a Phase 1 study in patients with recurrent metastatic, castration-resistant prostate cancer (MCRPC) (ClinicalTrials.gov Identifier: NCT02202447 ).

About Endocyte

Endocyte is a biopharmaceutical company and leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy in cancer and other serious diseases. Endocyte uses its proprietary technology to create novel SMDCs and companion imaging agents for personalized targeted therapies. The company's SMDCs actively target receptors that are expressed or over-expressed on diseased cells, relative to healthy cells. This targeted approach is designed to enable the treatment of patients with highly potent drugs into these cells. The companion imaging agents are designed to identify patients whose disease expresses the molecular target of the therapy and who therefore may be more likely to benefit from treatment. For more information, visit http://www.endocyte.com .

Stephanie Ascher, Stern Investor Relations, Inc., (212) 362-1200,

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Tenax Therapeutics Facing Class Action: DEC 28 Deadline

Updated Category News Views 65

Legal Storm Over Tenax Therapeutics Just what the doctor didn't order—legal headaches for Tenax Therapeutics, Inc. (NASDAQ:TENX). Yup, folks, buckle up because we're diving into another class action mudslinging match that’s setting the markets wagging. Berger Montague's law trebuchet is aimed squarely at Tenax and every investor should know the target’s outline....

Continue Reading
NestWorks' C500: Shaking Up CNC at Formnext 2026

Updated Category News Views 108

NestWorks C500: A Game Changer for Makers Folks, gather 'round, because NestWorks is turning heads with their C500 desktop CNC machine. As it lands firmly on TIME’s Best Inventions of 2026 list, this ain't just another gadget adorning a workshop—all eyes are on it at Formnext 2026. From November 17–20, Frankfurt is the stage where NestWorks plans to showcase how...

Continue Reading
Guangdong-US Trade: LED Screens, Beef & Trust Make Waves

Updated Category News Views 29

Guangdong's Economic Ballet with the U.S. Grab a cup of coffee, and let's unravel how Guangdong and the U.S. are tangoing their way through trade like nobody's business! Guangdong, the heavyweight champ for U.S.-China trade transactions, notched up a cool 685.27 billion yuan ($102 billion) in the first eight months of 2026. That's a healthy jump of 6.9% year on year, mind...

Continue Reading
Sasol AGM Resolutions Passed in One Swift Swing

Updated Category News Views 65

Sasol's AGM Delivers Smooth Sailing for Shareholders Can't say I'm surprised, but Sasol's annual general meeting on the 13th of November went off without a hitch—unless, of course, you're one of those folks who just loves fireworks at these gatherings. The entire set of resolutions danced through with a resounding "Aye," making it one heck of a day for anyone banking on...

Continue Reading
Ballard's Q3 2026: Navigating Losses and Bold Moves

Updated Category News Views 53

Ballard’s Financial Puzzles in Q3 2026 Riding the rough waters of the third quarter in 2026, Ballard Power Systems set out its stall with some eyebrow-raising numbers. This ain't the bustling diner vibe we normally see for a thriving business. The results paint a cautious picture sprinkled with strategic shifts that demand a keen eye. GeoPura Acquisition: A Strategic...

Continue Reading
LONGi's Four Paths to Global Green Development

Updated Category News Views 164

LONGi's Vision: A Cleaner, Greener Future Amidst the buzz at COP31 in Antalya, LONGi is making waves with promises of a cleaner future. They're not just throwing around eco-friendly slogans—this company's laying down real pathways to tackle climate change, one solar panel at a time. Aiming for Industrial Transformation LONGi's got their sights set on shaking up...

Continue Reading
MacKenzie-Childs Grinds Into Spotlight with Oprah's Nod

Updated Category News Views 40

Oprah's Golden Touch: 30 Years Strong Every year, there are a few select spots that brands covet like a hawk on a rabbit hunt. Getting on Oprah’s 'Favorite Things' list is surely one of them. Just like that, the MacKenzie-Childs Electric Salt and Pepper Grinder Set has muscled its way into the 2026 selection. Spare me the bells and whistles; this is like hitting the...

Continue Reading
CureGene's CG-0416: Promising Weight Loss Breakthrough

Updated Category News Views 125

Game-Changer in Weight Management? Oh, the obesity world is buzzing, folks! There's some big noise coming from CureGene, and it's catching the attention of every lab-coat smarty in town. They just tossed out some preclinical data on CG-0416 at Obesity Week 2026 that could shake up how we tackle weight loss. Anyone still clinging to their old diet books might want to take...

Continue Reading
Stark Future Amasses €150M, Revving Up Electric Bike Dominance

Updated Category News Views 115

Well, if you've been keeping your eye on electric vehicles, this is a story that might raise those eyebrows. Stark Future, a name perhaps not buzzing on every street just yet, has gone and done it—snagged over €150 million in fresh capital. Breaking Barriers with Record-breaking Numbers Stark Future didn't just make a ripple; they caused a tsunami. This buzzing...

Continue Reading
Jones Soda Expands into Nutrition with UCAN Deal

Updated Category News Views 59

Well, Jones Soda Co. (CSE: JSDA) is stirring the pot with its recent move to acquire the UCAN functional nutrition assets. Popped the news on November 12, 2026, and it turns out they've shelled out a cool $700,000 in cash and taken on $500,000 in liabilities for the privilege. This isn't some casual shuffle of dollars and cents—this one's a strategic gambit aimed at...

Continue Reading

Top 5 Most Recently Viewed Articles

Synovus Appoints New Chattanooga Market Leader for Growth

Updated Category News Views 502

Synovus Appoints Jim Vaughn as Chattanooga Market Executive Synovus has recently made headlines by appointing Jim Vaughn as the new Chattanooga market executive. He brings a wealth of experience and has a solid background in the financial sector, joining from Mauldin & Jenkins, where he honed his skills over a significant tenure. Leadership Role and Responsibilities In...

Continue Reading
Navigating Recruitment Trends in Maritime and Oil & Gas for 2025

Updated Category News Views 85

Trends Shaping Recruitment in the Maritime and Oil & Gas Industries Core Group Resources stands at the forefront of talent acquisition, guiding businesses toward sustainable growth by effectively identifying and nurturing the right talent. As we approach 2025, the company has unveiled a comprehensive analysis detailing the pivotal trends that will influence recruitment...

Continue Reading
Disney and Netflix Stocks Dip Amid Warner Bros. Merger News

Updated Category News Views 430

Disney and Netflix Stocks Experience a Decline Securities of Walt Disney Co (NYSE: DIS) and Netflix Inc (NASDAQ: NFLX) are witnessing a downward trend, likely influenced by recent reports concerning a significant business maneuver involving Warner Bros. Discovery Inc (NASDAQ: WBD). Speculation arises that a coalition led by Paramount Skydance Corp (NASDAQ: PSKY) is...

Continue Reading
Alpine Income Property Trust Launches New Preferred Stock Offering

Updated Category News Views 136

Alpine Income Property Trust Announces Public Offering Alpine Income Property Trust, Inc. (NYSE: PINE) has officially announced the launch of its public offering for the Series A Cumulative Redeemable Preferred Stock, which has a liquidation preference of $25.00 per share. This initiative reflects the company’s strategic approach to expanding its capital base and...

Continue Reading
Civitas Capital Strengthens Team with New Regional Director

Updated Category News Views 127

Civitas Capital Welcomes Rishabh Gandhi Civitas Capital is thrilled to announce a significant addition to our team: Rishabh Gandhi, who joins us as Regional Director for India and the Middle East. With over nine years of invaluable experience in the EB-5 investment industry, Rishabh brings a wealth of expertise, strategic insight, and an established network of...

Continue Reading